Barclays lowered the firm’s price target on Pacira BioSciences to $80 from $90 and keeps an Overweight rating on the shares. The company’s annual guidance was resumed with Exparel sales bracketing consensus, implying 8% growth at the higher end, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PCRX:
- Pacira price target raised to $71 from $69 at H.C. Wainwright
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
- Pacira sees 2023 EXPAREL net sales $570M-$580M
- Pacira reports Q4 adjusted EPS 80c, consensus 83c
- Pacira, LPGA partner to raise awareness of non-opioid pain management solutions